-
Alsevalimab: Targeting CD47 for Cancer Research and Treatment(Post)
Quick Facts About AlsevalimabWhat is Alsevalimab?Alsevalimab is a monoclonal antibody targeting CD47, a protein involved in immune evasion by cancer cells. By blocking CD47, Alsevalimab
CD39: A Novel Target to Overcome Immunosuppression in Cancer(Post)Introduction to CD39 and Cancer Immunosuppression CD39 is an ectonucleotidase enzyme that plays a crucial role in generating adenosine, a powerful immunosuppressive molecule within the tu
p53 Protein: Mutations, Cancer Signalling & Tumour Suppression(Post)Cancer Biology · Cell Signallingp53: Structure, Signalling, Regulation and Mutation in Cancerp53 is the most frequently mutated gene in human cancer, and the reason is structural: a single tetrameric
Unveiling Prezalumab: Targeting the Role of Anti-CD47 in Cancer Immunotherapy(Post)What You Need to Know About PrezalumabWhat is Prezalumab?Prezalumab is a monoclonal antibody designed to target CD47, a protein often overexpressed in cancer cells to evade immune detect
Can infection cause chronic disease?(Post)By Anusha Senevirante, Post-Doctoral researcher, Imperial College London With non-communicable diseases (or NCDs, which include heart disease, diabetes, ca
Next-Generation Cancer Therapy: Harnessing CAR-T Cells and the Tumor Microenvironment(Post)For decades, the fight against cancer has been a relentless battle of attrition, often with treatments that harm the body as much as the disease. But a new era of precision medicine is dawning, one th
Enhancing Cancer Research: Syngeneic Mouse Models and Immune Checkpoint Inhibitors(Post)Enhancing Cancer Research: Syngeneic Mouse Models and Immune Checkpoint Inhibitors A quick guide to Syngeneic Mouse Models Syngeneic Mouse Models Cancer research has seen rema
Transduction vs Transfection: Understanding Gene Delivery Techniques(Post)Techniques · Gene DeliveryTransduction vs Transfection: Understanding Gene Delivery TechniquesTransduction and transfection are the two main routes for introducing genetic material into cells. Transdu
In Vitro vs In Vivo: Complete Comparison + Selection Guide | Research Methods(Post)Discover the distinct roles of 'In Vivo' and 'In Vitro' in biological research, where one offers a natural context and the other precise control, both vital for scientific advancement.
SfN Neuroscience 2024(Post)SfN 2024: Meet Assay Genie at the Society for NeuroscienceAssay Genie is delighted to be attending SfN 2024 in Chicago, Illinois on 5th to the 9th of October at the McCormick Convention
Elotuzumab: Revolutionizing Multiple Myeloma Treatment and Research Applications(Post)Quick Facts About ElotuzumabWhat is Elotuzumab?Elotuzumab is a monoclonal antibody designed to enhance the immune system's ability to detect and destroy multiple myeloma cells. It target
Multiplex ELISA Protocol(Page) TLX as a Novel Therapeutic Target(Post)Danka Kozareva PhD Candidate, University College Cork The generation of neurons from stem cells The process of generating
Human Multiplex ELISA Panels(Page)Human Multiplex Cytokine ELISA Panels | Assay Genie
Navigating the Intricacies of Intracellular Flow Cytometry: Key Considerations(Post)In the evolving landscape of cellular biology, intracellular flow cytometry (ICFC) stands out as a powerful technique for analyzing the complexities within cells. This advanced method extends the
Loading Control Antibodies(Page)Loading Control Antibodies | GAPDH, \u03b2-Actin & Tubulin | Assay Genie
Praluzatamab: Unveiling the Promise of CD47-Targeted Therapy in Cancer Research(Post)Quick Facts About PraluzatamabWhat is Praluzatamab?Praluzatamab is an experimental monoclonal antibody that targets CD47, a “don’t eat me” signal used by cancer cells to evade immune des
SITC 2024 - Scientific Programme, Venue & Exhibition(Post)SITC 2024: Meet Assay Genie at the Society for Immunotherapy of Cancer Annual MeetingAssay Genie is delighted to be attending and exhibiting at SITC 2024 in Houston, Texas on Friday the
Durvalumab: Advancing Immunotherapy in Cancer Treatment(Post)Quick Facts About DurvalumabWhat is Durvalumab?Durvalumab (Imfinzi) is a PD-L1 checkpoint inhibitor used in immunotherapy to treat various cancers, including non-small cell lung cancer (
Multiple Sclerosis and Stem Cells(Post)By Sonika Singh PhD candidate, University of Nottingham A Devastating Disease Multiple Sclerosis (MS) is a chronic and inflammatory disease based on